About
QRGenetics is the developer of a powerful AI-supported drug discovery engine designed to identify potential therapies for common genetic diseases by uncovering new treatments for patients with similar rare-disease mutations.
From Genetic disease without treatment or unknown MOA to precision medicine for populations and address patent cliffs QRGenetics develop a powerful AI-supported drug discovery engine that utilizes exclusive spatial analytics and proprietary datasets, to rapidly discover novel drug-target combinations prompting new applications for soon-expired drugs.
QRGenetics’ drug discovery engine utilizes exclusive spatial analytics and proprietary omics datasets to rapidly produce novel drug and target combinations that are effective for multiple indications.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is QRGenetics' primary focus in drug discovery?
- QRGenetics focuses on developing an AI-supported drug discovery engine to identify potential therapies for common genetic diseases by uncovering new treatments for patients with similar rare-disease mutations.
- When was QRGenetics founded?
- QRGenetics was founded in June 2019.
- Where is QRGenetics headquartered?
- QRGenetics is headquartered in Tel Aviv-Yafo, Israel.
- How many employees does QRGenetics currently have?
- QRGenetics currently has 8 employees.
- What is QRGenetics' current funding stage?
- QRGenetics is currently in the Pre-Funding stage.
- Has QRGenetics received any grants?
- Yes, QRGenetics received a grant from the IIA in December 2023.
- What technologies does QRGenetics utilize in its drug discovery engine?
- QRGenetics utilizes Artificial Intelligence, Deep Learning, Machine Learning, Biologicals, and Genes in its drug discovery engine.
- What is the product stage of QRGenetics' offerings?
- QRGenetics' products, such as QR-755 and QR-172, are in the clinical trial stage.
- How many patents does QRGenetics hold?
- QRGenetics holds one patent.